ProMD Health

The medical aesthetics industry is experiencing one of the most sustained demand curves in the history of consumer health spending, and the investors best positioned to capture that growth are those who can identify credible, systems-driven brands before they scale. ProMD Health franchise represents exactly that kind of early-stage opportunity — a clinically credentialed, operationally refined aesthetic medicine brand that launched in October 2018, built a track record generating $1,000,000 per month in revenue by February 2020, and has only recently begun offering its model to franchise investors. Co-founded by Dr. George O. Gavrila, MD, and Scott Melamed, the company was built on a foundational premise that non-surgical aesthetic treatments deserve the same operational rigor and brand consistency as any top-tier consumer healthcare brand. Dr. Gavrila's clinical authority runs deep: he serves as a national trainer for Allergan, Galderma, and Suneva, three of the most prominent and influential brands in the global aesthetic medicine supply chain. Scott Melamed, who serves as President and CEO, brings the business infrastructure that translates clinical excellence into scalable franchise operations. The brand's corporate presence spans six active locations — Annapolis, Arlington, Ashburn, Bel Air, Bethesda, and Lafayette — all within the United States, providing a real-world laboratory from which the franchise system has been engineered. With three total franchised units currently operating and zero company-owned units, ProMD Health is at the precise inflection point where early franchise investors have historically captured the greatest territory advantages, brand equity upside, and operational support attention. Independent analysis of this franchise must be grounded in the understanding that ProMD Health is not a startup in the traditional sense — it is a proven clinical business model now being systematized for multi-operator scale.

The U.S. medical aesthetics market is one of the fastest-growing segments within the broader $532 billion global wellness economy. According to industry research, the U.S. medical spa market alone was valued at approximately $15.6 billion in 2022 and is projected to grow at a compound annual growth rate exceeding 14% through 2030, driven by a confluence of powerful consumer trends. The single largest driver is demographic: an aging U.S. population that is simultaneously more health-conscious and more aesthetics-aware than any prior generation, with adults aged 35 to 65 representing the core consumer base for non-surgical treatments including neurotoxins, dermal fillers, body contouring, and skin rejuvenation. A second critical tailwind is the destigmatization of aesthetic treatments among younger cohorts — the American Society of Plastic Surgeons reported that non-surgical cosmetic procedures have grown by more than 200% over the past decade, with injectable treatments representing the single largest procedural category. The shift away from surgical interventions toward non-invasive, low-downtime procedures is a secular trend that benefits brands like ProMD Health franchise structurally, since their entire model is built around non-surgical treatments requiring no hospital affiliation or surgical suite infrastructure. The competitive landscape in medical aesthetics is still largely fragmented at the national level, with regional medspa operators and independent physician practices holding the majority of market share, creating significant white space for credentialed franchise systems that can deliver consistent quality and brand recognition across markets. Unlike salon services or fitness concepts, medical aesthetic services carry significant clinical and regulatory barriers to entry that naturally protect franchisees operating within a compliant, physician-led framework. This is the industry environment into which ProMD Health is deploying its franchise opportunity, and the macroeconomic signals are unambiguously favorable for long-term franchise investors.

The ProMD Health franchise investment profile reflects the realities of building a medical aesthetic practice — a category that sits at the intersection of healthcare real estate, clinical equipment, licensed staff compensation, and marketing infrastructure. The company does not publicly disclose its franchise fee, total investment range, royalty rate, or advertising fund contribution in materials accessible outside of its Franchise Disclosure Document, which is consistent with the early-stage nature of its franchising program and the legal framework governing FDD disclosures. What this means for prospective investors is that a thorough review of the FDD becomes the non-negotiable first step in due diligence. For context, the broader medical spa franchise category typically features initial franchise fees ranging from $35,000 to $75,000, with total initial investment ranges that span from approximately $250,000 on the low end for conversion or suite-based formats to over $1,000,000 for full build-out flagship practices in premium markets. Ongoing royalty rates in the medical aesthetics franchise segment commonly run between 5% and 8% of gross revenue, with marketing fund contributions typically adding an additional 1% to 2%. For investors evaluating the ProMD Health franchise cost relative to category norms, these benchmarks provide a preliminary framework, but the actual figures disclosed in the FDD will govern any investment decision. Financing considerations are significant in this category given the capital intensity of clinical equipment, technology platforms, and build-out costs — CareCredit, Alle by Cherry, and Affirm are all financing platforms that ProMD Health has integrated on the patient side of the business, which reduces collection friction and supports revenue per visit. Prospective franchisee investors should engage a franchise attorney and accountant with healthcare industry experience before executing any agreement, given the regulatory complexity layered atop standard franchise economics.

Daily operations within a ProMD Health franchise are built around what the company calls the "ProMD Way" — a systematized operational philosophy developed over years of running its own corporate locations across multiple markets. Franchisees are not expected to have a prior medical background to operate the business, though the presence of licensed medical professionals on the clinical team is a fundamental operational requirement given the nature of injectable and non-surgical aesthetic services. The training program includes both on-site and off-site medical training led by Dr. Gavrila himself, whose national trainer credentials with Allergan, Galderma, and Suneva position the ProMD training program at a distinctly higher clinical standard than many competing medspa franchise systems. Jessica, a Managing Partner with over 15 years of experience in medical aesthetics, adds a further layer of operational mentorship available to franchisees entering the system. The brand's support structure is designed to provide franchisees with a vetted system, brand support, tools, and ongoing training — a framework built specifically to empower physicians and clinicians who want to own their aesthetic practices rather than remain employed practitioners. Territory structure and exclusivity details are governed by the FDD and individual franchise agreements, and prospective investors should specifically interrogate the geographic protections offered in their target market during the discovery process. The operational model appears oriented toward owner-operators or physician-owners who are actively involved in their practice, consistent with the clinical credibility requirements of the medical aesthetic category. Multi-unit development within the ProMD Health system is a natural pathway as the brand's existing corporate footprint across six markets demonstrates the scalability of the model under centralized leadership.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document, which means that ProMD Health has elected not to provide average revenue, median revenue, or profit margin figures to prospective franchisees through formal FDD channels. This is a meaningful data point for investors: while approximately 60% of franchisors provide financial performance representations in their FDD, the remaining 40% — often brands at earlier stages of their franchise programs — do not. The absence of Item 19 disclosure does not indicate poor performance; it frequently reflects the early stage of a franchising program where the unit count is insufficient to produce statistically meaningful averages. What can be established from publicly available information is that ProMD Health as a corporate operating entity reported $1,000,000 per month in revenue as of February 2020 — an annualized run rate of $12 million across its then-existing corporate locations. That figure represents aggregate corporate performance, not a per-unit average, and investors should not extrapolate it directly to individual franchise unit projections. For benchmarking purposes, the medical spa industry reports average annual revenues per location ranging from approximately $1.2 million to $2.5 million depending on market, service mix, and patient volume, with top-performing medspa practices in premium markets exceeding $4 million annually. ProMD Health franchise revenue potential in any given market will be a function of local demographics, competitive density, franchisee execution quality, and marketing investment — all variables that prospective investors should model conservatively and validate through franchisee validation calls with existing operators in the system. The brand's accolades — including three-time Best of Annapolis, West County, and Eastern Shore; recognition in Inc. 5000; Baltimore Lifestyle; Faces of Annapolis and Baltimore; WWE Divas coverage; and Better Business Bureau Torch Awards — provide qualitative evidence of strong consumer and institutional reputation in its home markets.

ProMD Health's growth trajectory reflects the disciplined, market-validated approach of a brand that prioritized operational depth before franchise scale. Launching as a business in October 2018, the company built and refined its clinical and operational model across six corporate locations before transitioning to a franchise model — a sequencing that separates serious franchise systems from concept-only offerings that franchise before proving the model. Currently operating with three total franchised units, all within the United States, the brand is at the foundational stage of what could be a significant national franchise footprint given the structural tailwinds in the medical aesthetics category. Dr. Gavrila's position as a national trainer for Allergan, Galderma, and Suneva creates a meaningful competitive moat: these relationships provide ProMD Health franchisees with access to product knowledge, training resources, and potentially preferential pricing structures that independent medspa operators cannot easily replicate. The brand's recognition across regional media and industry award programs — including Inc. 5000, a designation that requires companies to demonstrate significant revenue growth — establishes that ProMD Health has executed at a meaningful commercial scale, not simply at a boutique clinical level. The company's leadership team, combining Dr. Gavrila's clinical authority and training network with Scott Melamed's business development and executive leadership as President and CEO, represents a complementary founding duo capable of navigating both the clinical and commercial dimensions of franchise growth. As the aesthetic medicine category continues its double-digit annual growth trajectory, brands with authentic clinical credibility, multi-location operational experience, and established supplier relationships are positioned to attract both franchise investors and the highly credentialed practitioners who want to participate in practice ownership without building from scratch.

The ideal ProMD Health franchise candidate is likely a physician, nurse practitioner, registered nurse, or licensed aesthetic clinician who wants to own a practice rather than be employed by one — or alternatively, a business-minded investor with the capital and management bandwidth to assemble a qualified clinical team under the ProMD operational framework. The brand's support structure, which includes training led by Dr. Gavrila and operational mentorship from a Managing Partner with 15 years of medical aesthetics experience, is specifically calibrated to give clinicians a faster path to practice ownership than building independently. For investor-operators without clinical backgrounds, the key operational question is the physician oversight structure required by state medical practice laws, which vary by jurisdiction and materially affect how a non-clinician can legally structure ownership and operations. Geographic opportunity exists across the United States, with the brand's current concentration in the Mid-Atlantic corridor — Maryland and Virginia — suggesting that the earliest franchisees outside that core territory will benefit from first-mover positioning in their respective markets. The timeline from signed franchise agreement to open practice will depend on real estate, build-out or conversion scope, licensing timelines, and staff hiring — all variables common to the medspa category that prospective investors should budget for conservatively in their pre-opening capital planning. Multi-unit development is a logical pathway for investors who can demonstrate operational capability, given that the medical aesthetics consumer base is concentrated in specific demographic markets where multiple locations can share marketing infrastructure and staff training resources efficiently.

Any serious investor evaluating the ProMD Health franchise opportunity is confronting a fundamental question that every franchise investment decision reduces to: is this the right brand, at the right stage, in the right industry, for my capital and capabilities? The analysis above suggests that the industry answer is unambiguously yes — the medical aesthetics market is growing at over 14% annually, the competitive landscape remains fragmented, and consumer demand for non-surgical aesthetic treatments is a durable, multi-decade trend. The brand answer is compelling but early-stage: ProMD Health has demonstrated $1,000,000 per month in revenue at the corporate level, earned Inc. 5000 recognition, accumulated multiple Best of market awards, and built clinical credibility through leadership that trains practitioners for Allergan, Galderma, and Suneva nationally. With a current FPI Score of 58, which PeerSense classifies as Moderate, the brand reflects the inherent risk profile of an early-stage franchise system that has not yet accumulated the multi-year unit performance data that higher-scoring established franchises carry. That Moderate score is not a disqualifier — virtually every franchise system that is dominant today scored in that range during its early franchising years — but it is an accurate signal that investors must conduct rigorous independent due diligence rather than relying on brand marketing materials. PeerSense provides exclusive due diligence data including SBA lending history, FPI score analysis, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark ProMD Health against other medical aesthetics and personal care franchise opportunities at a granular level. The combination of a high-growth industry, a clinically credentialed founding team, an early-stage franchise footprint with first-mover territory advantages, and the due diligence infrastructure available through independent research makes this a franchise profile worthy of serious exploration. Explore the complete ProMD Health franchise profile on PeerSense to access the full suite of independent franchise intelligence data.